{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:24:05Z","timestamp":1792664645351,"version":"4.5.0"},"reference-count":29,"publisher":"SAGE Publications","issue":"14","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The goal of this study was to complete the first Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) based systematic review of dupilumab use in patients living with human immunodeficiency virus (HIV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature review was performed using PubMed, Google Scholar, Ovid MEDLINE, and Science Direct databases as well as an internal review using University of Virginia\u2019s electronic medical record system. All reports of dupilumab use in patients with confirmed HIV were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>14 published cases comprising 23 patients were identified and included in the review. Additionally, four unpublished cases from our own institution were included for a final cohort of 27 patients. A total of 25 patients (96%) were observed to have a clinical response, defined as improvement or complete resolution of their cutaneous or asthmatic symptoms. In 100% of patients, viral load improved or did not change, and in 80% of patients, CD4 counts remained stable. Side effects occurred in 48% of patients but were self-limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion and Conclusions<\/jats:title>\n                    <jats:p>All reported cases indicate that dupilumab is safe in patients with HIV with stable CD4 counts and low viral loads. Most patients had significant improvement within 2\u00a0months of treatment with mild side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09564624221129406","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T18:15:55Z","timestamp":1665771355000},"page":"1165-1173","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["The use of dupilumab in patients with HIV"],"prefix":"10.1177","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1459-0999","authenticated-orcid":false,"given":"Nicole","family":"Edmonds","sequence":"first","affiliation":[{"name":"School of Medicine, University of Virginia, Charlottesville, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Zhao","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Virginia, Charlottesville, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H","family":"Flowers","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Virginia, Charlottesville, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"bibr1-09564624221129406","unstructured":"Highlights of prescribing information: dupixent (dupilumab) injection, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761055s007lbl.pdf (accessed February 10 2022)."},{"key":"bibr2-09564624221129406","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.12.022"},{"key":"bibr3-09564624221129406","unstructured":"A randomized, double blind, placebo-controlled, multi-center, parallel group study to evaluate the efficacy and safety of dupilumab in patients with prurigo nodularis who are inadequately controlled on topical prescription therapies or when those therapies are not advisable, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04183335 (updated February 17 2022. accessed June 23 2022)."},{"key":"bibr4-09564624221129406","unstructured":"Study of dupilumab. (REGN668\/SAR231893) monotherapy administered to adult patients with moderate-to-severe atopic dermatitis (SOLO 2). ClinicalTrials.gov Identifier: NCT02277769, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02277769 (updated June 2 2020, accessed 17 December 2021)."},{"key":"bibr5-09564624221129406","unstructured":"Howick J, Chalmers I, Paul G, OCEBM Levels of Evidence Working Grou, et al. Oxford centre for evidence-based medicine 2011 levels of evidence oxford centre for evidence-based medicin, http:\/\/www.cebm.net\/wp-content\/uploads\/2014\/06\/CEBM-Levels-of-Evidence-2.1.pdf (2011, accessed June 20 2022)."},{"key":"bibr6-09564624221129406","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.09.023"},{"key":"bibr7-09564624221129406","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18222"},{"key":"bibr8-09564624221129406","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3201"},{"key":"bibr9-09564624221129406","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15471"},{"key":"bibr10-09564624221129406","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15499"},{"key":"bibr11-09564624221129406","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2021.0113"},{"key":"bibr12-09564624221129406","doi-asserted-by":"publisher","DOI":"10.5070\/D327854709"},{"key":"bibr13-09564624221129406","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000501"},{"key":"bibr14-09564624221129406","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14278"},{"key":"bibr15-09564624221129406","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14159"},{"key":"bibr16-09564624221129406","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14271"},{"key":"bibr17-09564624221129406","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14244"},{"key":"bibr18-09564624221129406","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100848"},{"key":"bibr19-09564624221129406","doi-asserted-by":"publisher","DOI":"10.15570\/actaapa.2021.17"},{"key":"bibr20-09564624221129406","doi-asserted-by":"publisher","DOI":"10.4103\/ijstd.IJSTD_22_17"},{"key":"bibr21-09564624221129406","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(90)90154-v"},{"key":"bibr22-09564624221129406","doi-asserted-by":"publisher","DOI":"10.1016\/s0091-6749(05)80042-9"},{"key":"bibr23-09564624221129406","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(93)90208-3"},{"key":"bibr24-09564624221129406","doi-asserted-by":"publisher","DOI":"10.1084\/jem.180.2.489"},{"key":"bibr25-09564624221129406","volume-title":"StatPearls","author":"Li R","year":"2021"},{"key":"bibr26-09564624221129406","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.08.051"},{"key":"bibr27-09564624221129406","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1853024"},{"key":"bibr28-09564624221129406","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.05.006"},{"key":"bibr29-09564624221129406","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624221129406","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09564624221129406","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624221129406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:43:52Z","timestamp":1777675432000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09564624221129406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":29,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1177\/09564624221129406"],"URL":"https:\/\/doi.org\/10.1177\/09564624221129406","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]}}}